Annual direct cost of dry eye in Japan

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 755-760

  Mizuno, Yoshinobu ^a   Yamada, Masakazu ^a   Shigeyasu, Chika ^a  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Burden of disease; Cost; Dry eye; Eyedrops; Quality of life

Indexed keywords

ANTIINFECTIVE AGENT; ARTIFICIAL TEAR; CHONDROITIN SULFATE; EYE DROPS; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; DRY EYE; FEMALE; HEALTH CARE COST; HEALTH CARE SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL RECORD; OUTPATIENT CARE; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 84863469113     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S30625     Document Type: Article

References (17)

1. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102-S106.
2. Yamada M. Dry eye syndrome: concept, pathogenesis, and therapeutic modalities based on the new definition. J Jpn Ophthalmol Soc. 2008; 113:541-552.
3. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-621.
4. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: comparisons to a US normative sample. Invest Ophthalmol Vis Sci. 2005;46:46-50.
5. Mizuno Y, Yamada M, Miyake Y. Association between clinical diagnostic tests and health-related quality of life surveys in patients with dry eye syndrome. Jpn J Ophthalmol. 2010;54:259-265.
6. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409-415.
7. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412-1419.
8. Clegg JP, Guest JF, Lehman A, Smith AF. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006;13:263-274.
9. Enzenauer RW, Kao A, Williams T, Lambert RW. Relative costs of various preserved artificial tear solutions for the treatment of dry eye conditions. Eye Contact Lens. 2003;29:238-240.
10. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea. 2004;23:751-761.
11. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin. 2011;27:1041-1048.
12. Shimazaki J, Tsubota K, Kinoshita S, et al. Definition and diagnosis of dry eye 2006. Atarashii Ganka. 2007;24:181-184. Japanese.
13. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-412.
14. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124:12-19.
15. Schmier JK, Covert DW, Robin AL. First-year treatment costs among new initiators of topical prostaglandin analogs. Clin Ophthalmol. 2009;3:637-644.
16. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology. 1989;96:255-264.
17. Cruess AF, Zlateva G, Xu X, et al. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics. 2008;26:57-73.